{
    "clinical_study": {
        "@rank": "244",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 13, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04323800"
        },
        "id_info": {
            "org_study_id": "IRB00245634",
            "nct_id": "NCT04323800"
        },
        "brief_title": "Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19",
        "acronym": "CSSC-001",
        "official_title": "Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johns Hopkins University",
                "agency_class": "Other"
            }
        },
        "source": "Johns Hopkins University",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No",
            "is_us_export": "No"
        },
        "brief_summary": {
            "textblock": "Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control\n      (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day\n      28."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "May 1, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "January 2023"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "December 31, 2022"
        },
        "phase": "Phase 2",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "intervention_model_description": "1:1 ratio",
            "primary_purpose": "Treatment",
            "masking": "Triple (Participant, Care Provider, Investigator)"
        },
        "primary_outcome": {
            "measure": "Cumulative incidence of composite outcome of disease severity",
            "time_frame": "Day 28",
            "description": "The cumulative incidence of composite outcome of disease severity will be used in assessing the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to COVID-19. This will be determined with the presence or occurrence of at least one of the following:\nDeath\nRequiring mechanical ventilation and/or in ICU\nnon-ICU hospitalization, requiring supplemental oxygen;\nnon-ICU hospitalization, not requiring supplemental oxygen;\nNot hospitalized, but with clinical and laboratory evidence of COVID-19 infection\nNot hospitalized, no clinical evidence of COVID-19 infection, but with positive PCR for SARS-CoV-2"
        },
        "secondary_outcome": [
            {
                "measure": "Anti-SARS-CoV-2 titers",
                "time_frame": "Baseline",
                "description": "Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups anti-SARS-CoV-2 titers at day 0 (baseline)."
            },
            {
                "measure": "Anti-SARS-CoV-2 titers",
                "time_frame": "Day 1",
                "description": "Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups anti-SARS-CoV-2 titers at day 1."
            },
            {
                "measure": "Anti-SARS-CoV-2 titers",
                "time_frame": "Day 3",
                "description": "Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups anti-SARS-CoV-2 titers at day 3."
            },
            {
                "measure": "Anti-SARS-CoV-2 titers",
                "time_frame": "Day 7",
                "description": "Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups anti-SARS-CoV-2 titers at day 7."
            },
            {
                "measure": "Anti-SARS-CoV-2 titers",
                "time_frame": "Day 14",
                "description": "Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups anti-SARS-CoV-2 titers at day 14."
            },
            {
                "measure": "Anti-SARS-CoV-2 titers",
                "time_frame": "Day 90",
                "description": "Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups anti-SARS-CoV-2 titers at day 90."
            },
            {
                "measure": "Rates of SARS-CoV-2 PCR positivity",
                "time_frame": "Up to day 28",
                "description": "Compare the rates of SARS-CoV-2 PCR positivity (RT-PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups at days 0, 7, 14 and 28."
            },
            {
                "measure": "Duration of SARS-CoV-2 PCR positivity",
                "time_frame": "Up to day 28",
                "description": "Compare the duration (days) of SARS-CoV-2 PCR positivity (RT-PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups at days 0, 7, 14 and 28."
            },
            {
                "measure": "Peak quantity levels of SARS-CoV-2 RNA",
                "time_frame": "Up to day 28",
                "description": "Compare the peak quantity levels of SARS-CoV-2 RNA amongst the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups at days 0, 7, 14 and 28 days."
            },
            {
                "measure": "Cumulative incidence of disease severity",
                "time_frame": "up to Day 28",
                "description": "Cumulative incidence of disease severity between the anti-SARS-CoV-2 convalescent plasma and control groups after individuals develop SARS-CoV-2 infection. Severity of disease will be measured using a clinical event scale of disease severity (evaluated up to Day 28):\nDeath\nRequiring mechanical ventilation and/or in ICU\nnon-ICU hospitalization, requiring supplemental oxygen;\nnon-ICU hospitalization, not requiring supplemental oxygen;\nNot hospitalized, but with clinical and laboratory evidence of COVID-19 infection"
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "150"
        },
        "condition": [
            "Coronavirus",
            "Convalescence"
        ],
        "arm_group": [
            {
                "arm_group_label": "High titer anti-SARS-CoV-2 plasma",
                "arm_group_type": "Experimental",
                "description": "Participants with High titer anti-SARS-CoV-2 plasma."
            },
            {
                "arm_group_label": "SARS-CoV-2 non-immune plasma",
                "arm_group_type": "Active Comparator",
                "description": "Participants with SARS-CoV-2 non-immune plasma."
            }
        ],
        "intervention": [
            {
                "intervention_type": "Biological",
                "intervention_name": "Anti- SARS-CoV-2 Plasma",
                "description": "SARS-CoV-2 convalescent plasma (1 unit; ~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and was found to have a titer of neutralizing antibody >1:64)",
                "arm_group_label": "High titer anti-SARS-CoV-2 plasma"
            },
            {
                "intervention_type": "Biological",
                "intervention_name": "SARS-CoV-2 non-immune Plasma",
                "description": "Standard plasma collected prior to December 2019",
                "arm_group_label": "SARS-CoV-2 non-immune plasma"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must be 18 years of age or older\n\n          -  Close contact* exposure to person with COVID-19 within 96 hours of enrollment (and 120\n             hours of receipt of plasma)\n\n        High risk exposure as defined by CDC: Living in the same household as, being an intimate\n        partner of, or providing care in a nonhealthcare setting (such as a home) for a person with\n        symptomatic laboratory-confirmed COVID-19 infection without using recommended precautions\n        for home care and home isolation\n\n        AND\n\n        Higher risk for severe illness as defined by CDC (any of the following):\n\n          -  65 years of age\n\n               -  Residence in a nursing home or long-term care facility 3.3 -Chronic lung disease\n                  or moderate to severe asthma 3.4 -Heart disease 3.5 -Immunocompromising condition\n                  including cancer treatment\n\n               -  Severe obesity (body mass index [BMI] >40)\n\n               -  Uncontrolled diabetes\n\n               -  Renal failure\n\n               -  Liver disease\n\n        Exclusion Criteria:\n\n          -  Receipt any blood product in past 120 days\n\n          -  Psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion\n             of the principal investigator, would affect subject safety and/or compliance\n\n          -  Symptoms consistent with COVID-19 infection (fevers, acute onset cough, shortness of\n             breath) at time of screening\n\n          -  Nucleic acid testing evidence of COVID-19 infection at time of screening\n\n          -  History of prior reactions to transfusion blood products\n\n          -  Inability to complete therapy with the study product within 24 hours after enrollment"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "Accepts Healthy Volunteers"
        },
        "overall_official": {
            "last_name": "Shmuel Shoham, MD",
            "role": "Principal Investigator",
            "affiliation": "Johns Hopkins University"
        },
        "overall_contact": {
            "last_name": "Shmuel Shoham, MD",
            "phone": "410-614-6702",
            "email": "TOID_CRC@jhmi.edu"
        },
        "verification_date": "April 2020",
        "study_first_submitted": "March 24, 2020",
        "study_first_submitted_qc": "March 26, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "March 27, 2020"
        },
        "last_update_submitted": "April 6, 2020",
        "last_update_submitted_qc": "April 6, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "April 8, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "keyword": "COVID-19",
        "condition_browse": {
            "mesh_term": [
                "Coronavirus Infections",
                "Convalescence"
            ]
        },
        "patient_data": {
            "sharing_ipd": "No",
            "ipd_description": "Sharing is governed by Johns Hopkins University Institutional Guidelines"
        }
    }
}